Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine
Reference26 articles.
1. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18 (3): 269–85.
2. He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307–316
3. McCool R, Wilson K, Arber M, Fleetwood K, Toupin S, Thom H et al (2019) Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord 29:55–61
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf. Reached at January 1, 2022.
5. https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus. Reached at January 1, 2022.